Keyword: production

Egis expands its portfolio with active pharmaceutical ingredient contract development and contract manufacturing

Egis Pharmaceuticals PLC, celebrating the 110th anniversary of its foundation this year, is expanding its usual activities with new elements thanks to investments exceeding a total value of more than HUF 100 billion in Hungary over the past decade.  Egis, one of the leading generic pharmaceutical companies in Eastern and Central Europe, now offers drug substance contract development and contract manufacturing services under the name of Egis Pharma Services to both existing and new pharmaceutical partners.

More

Egis announces further investments at its Körmend site

Over the next few years, Egis Pharmaceuticals PLC will invest EUR 21.1 million to increase its capacity at its Körmend site. To finance these developments, Egis will use its own capital and a government subsidy of EUR 3.4 million – announced Csaba Poroszlai, CEO of Egis. In total, the company will devote more than EUR 50 million to the development of the Körmend site of Egis since 2019.

More

Gran Prize - Egis Innovation for Sustainability

Egis has developed a new procedure for the dehalogenation of technological wastewaters. In 2018, the Swedish Chamber of Commerce in Hungary recognized the innovation with the Gran Prize Interdisciplinary Innovative award.

More

Active Agent Production Renewed

By renewing our active agent base, we wish to simultaneously raise the rate of our active agents produced internally in a reliable quality and at a competitive price as well as to increase our exports.

More
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox